Health Care·Biotechnology·$351.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.11 | N/A | +0.10% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $3.11 | N/A | +0.10% |
| Revenue | N/A | N/A | N/A |
Tone: Neutral
Management acknowledged the challenges in the market but emphasized their commitment to innovation. They did not offer specific guidance for future performance.
Management did not provide specific revenue guidance for the upcoming quarters.
The company remains focused on its pipeline and ongoing product launches.
AbbVie's earnings report shows a slight beat on EPS, but the lack of revenue figures and guidance may have disappointed some investors. The stock fell by 2.16% in reaction, indicating cautious sentiment in the market. Investors may be looking for more clarity on future performance and product pipeline developments.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ALPHABET INC Class C
Jul 27, 2021